Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis

2022 ◽  
Author(s):  
Jaecheol Kang ◽  
Woohyung Lee ◽  
Jaehoon Shin ◽  
Yejong Park ◽  
Jae Woo Kwon ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Propensity Score ◽  
Ampullary Cancer

scholarly journals Controversial Oncologic Benefit of Adjuvant Therapy for Ampullary Cancer: A Propensity Score Matched Analysis

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S57
Author(s):  
H. Kim ◽  
W. Lee ◽  
K.B. Song ◽  
J.H. Lee ◽  
D.W. Hwang ◽  
...  
Keyword(s):  
Propensity Score ◽  
Adjuvant Therapy ◽  
Ampullary Cancer

scholarly journals Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis

Cancer ◽  
2015 ◽  
Vol 122 (5) ◽  
pp. 693-701 ◽  
Author(s):  
Brett L. Ecker ◽  
Matthew T. McMillan ◽  
Jashodeep Datta ◽  
Ronac Mamtani ◽  
Bruce J. Giantonio ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Small Bowel ◽  
Propensity Score ◽  
Small Bowel Adenocarcinoma

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 520-520
Author(s):  
Joseph A. Sparano ◽  
Anne M. O'Neill ◽  
Noah Graham ◽  
Donald W. Northfelt ◽  
Chau T. Dang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Early Breast Cancer ◽  
Inflammatory Cytokines ◽  
Multiple Testing ◽  
Distant Recurrence ◽  
Stage Ii ◽  
P Value

520 Background: Systemic inflammation may contribute to cancer progression (PMC2803035), including recurrence of early breast cancer (PMC4828958). We hypothesized that inflammatory cytokines and/or chemokines may be associated with distant recurrence (DR). Methods: We performed a case:control study in women with stage II-III Her2-negative breast cancer, all of whom had surgery and adjuvant chemotherapy (doxorubicin/cyclophosphamide, then weekly paclitaxel) with/without bevacizumab, plus endocrine therapy if ER-positive (PMC6118403). Propensity score matching was used to identify approximately 250 case:control pairs (with/without DR). Serum samples obtained before adjuvant chemotherapy were analyzed using the MSD V-Plex Human Cytokine 36-Plex Kit for detection of human cytokines and chemokines involved in the Th1/Th2 pathway, chemotaxis, the Th17 pathway, angiogenesis, and immune system regulation. Conditional logistic regression analysis, with models fit via maximum likelihood, were used to estimate hazard ratios (HRs) and test for associations. Due to skewed nature of cytokines, HRs are reported on log base 2 scale. If adjusted for multiple testing including 36 markers, a p value of < 0.0014 would be required for statistical significance. Results: A total 249 matched pairs (498 patients) were identified. Covariates used for propensity score matching included age, menopausal status (post 54% vs. pre/peri 46%), ER/PR status (one/both pos 64% vs. both neg 36%) tumor size ( < = 2cm 17%, > 2-5cm 67%, > 5cm 16%) nodal status (neg 15%,1-3+ 32%, 4+ 53%), and grade (low 3%, int. 31%, high 66%). The only biomarker associated with a significantly increased DR risk when adjusted for multiple testing was the proinflammatory cytokine IL-6 (HR 1.37, 95% confidence intervals [CI] 1.15, 1.65, p = 0.0006). Others associated with a 2-sided p value < 0.05 included the chemokine MDC(macrophage-derived chemokine/CCL22) (1.90, 95% CI 1.17, 3.1, p = 0.0098), the T helper cell inflammatory cytokine IL-17A (HR 1.36, 95% CI 1.10, 1.67, p = 0.0052), and the cytokine VEGF-A (HR 1.13 for, 95% CI 1.01, 1.27, p = 0.037). There was no statistical interaction between VEGF-A and bevacizumab benefit. The median and mean value for IL-6 was 0.95 and 7.5 pg/ml (range 0.04-2761.24 pg/ml). Conclusions: This analysis provides level 1B evidence indicating that higher levels of the cytokine IL-6 at diagnosis are associated with a significantly higher DR risk in high-risk stage II-III breast cancer despite optimal adjuvant systemic therapy. This provides a foundation for confirmatory validation of IL-6 as a prognostic biomarker, and potentially as a predictive biomarker for testing therapeutic interventions targeting the IL-6/JAK/STAT3 pathway. Supported by NCI U10CA180820,180794,180821; UG1CA189859,232760,233290, 233196; Komen Foundation; Breast Cancer Research Foundation. Clinical trial information: NCT00433511.

scholarly journals Adjuvant Chemotherapy for Low-Clinical-Risk Breast Cancer Defined by Modified Version of Adjuvant! Online: A Propensity Score Matched SEER Analysis

Breast Care ◽  
2020 ◽  
pp. 1-7
Author(s):  
Jiefeng Huang ◽  
Zhiyong Wu ◽  
Zechun Zhang ◽  
Jie Li ◽  
Yunhai Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Propensity Score ◽  
Clinical Risk ◽  
Risk Breast Cancer

scholarly journals Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis

2018 ◽  
Vol 29 ◽  
pp. viii260-viii261
Author(s):  
S. Yadav ◽  
H. Xie ◽  
I.B. Riaz ◽  
P. Sharma ◽  
A. Mahipal ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Propensity Score

Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis

2019 ◽  
Vol 45 (8) ◽  
pp. 1432-1438 ◽  
Author(s):  
Siddhartha Yadav ◽  
Hao Xie ◽  
Irbaz Bin-Riaz ◽  
Prabin Sharma ◽  
Urshila Durani ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Propensity Score

scholarly journals Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

2018 ◽  
Vol 6 (10) ◽  
pp. 373-383 ◽  
Author(s):  
Deng-Feng Ren ◽  
Fang-Chao Zheng ◽  
Jun-Hui Zhao ◽  
Guo-Shuang Shen ◽  
Raees Ahmad ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Propensity Score ◽  
D2 Gastrectomy ◽  
Matched Study

Impact of earlier adjuvant chemotherapy after surgery on prognosis in patients with operable gastric cancer: A propensity score matched analysis.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 4057-4057
Author(s):  
Mi-Jung Kim ◽  
Keun Won Ryu ◽  
Bang Wool Eom ◽  
Hong Man Yoon ◽  
Rak Yeong Son ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Propensity Score
Sign in / Sign up

Export Citation Format

Share Document